TCGA-78-7536-01A-11R-2066-07
— · cohortA3
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA3
- subtype
- cohortA3
- age_years
- 69
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.570
- G2M_CHECKPOINT+0.530
- MYC_TARGETS_V1+0.510
- MYC_TARGETS_V2+0.430
- DNA_REPAIR+0.350
- MITOTIC_SPINDLE+0.350
- OXIDATIVE_PHOSPHORYLATION+0.330
- UNFOLDED_PROTEIN_RESPONSE+0.320
- PROTEIN_SECRETION+0.290
- MTORC1_SIGNALING+0.270
Top 10 suppressed
- ANGIOGENESIS-0.500
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.490
- HEDGEHOG_SIGNALING-0.460
- COAGULATION-0.440
- MYOGENESIS-0.420
- APICAL_JUNCTION-0.380
- APICAL_SURFACE-0.320
- KRAS_SIGNALING_DN-0.300
- P53_PATHWAY-0.300
- INFLAMMATORY_RESPONSE-0.290
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR12202462 | — | — | 0.906 |
| 2 | R181 | — | — | 0.904 |
| 3 | MBCproject_0227_T2_RNA | — | B | 0.895 |
| 4 | BS_DFGS950G | high-grade glioma | — | 0.894 |
| 5 | BS_052PZFMK | high-grade glioma | — | 0.892 |
| 6 | TCGA-C8-A1HK-01A-21R-A13Q-07 | — | C | 0.887 |
| 7 | TCGA-ZF-A9RN-01A-11R-A42T-07 | — | — | 0.887 |
| 8 | TCGA-44-7669-01A-21R-2066-07 | — | cohortA3 | 0.884 |
| 9 | TCGA-4Z-AA80-01A-11R-A39I-07 | — | — | 0.882 |
| 10 | TCGA-GC-A4ZW-01A-11R-A26T-07 | — | — | 0.880 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 19 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.570 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.530 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.510 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.430 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.350 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.350 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.330 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.320 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.290 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.270 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.260 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.220 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.220 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.200 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.190 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.120 | Inavolisib | — uncovered |
| PEROXISOME | 0.050 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.040 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.040 | Idelalisib | — uncovered |